Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

JetBrains has announced that it is open-sourcing its new machine learning model designed for software engineering systems, Mellum2. This comes a little over a year after the company open-sourced the ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Each component individually is stable. Instability emerges at the level of their integration. When environmental complexity increases, planners expand more nodes. When ambiguity grows, the Behavior ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of ...

Recursion is expected to report a Q2 loss of 35 cents per share on $14.38 million in revenues. Collaborations with Roche, Merck, and NVIDIA continue to support RXRX's evolving drug discovery efforts.

The generalized linear model (GLM) framework provides statisticians with a powerful and adaptable approach to modeling different data types beyond the limitations of the traditional linear regression ...